A5020027481- Hair Growth and Disorders
- Dermatologic Treatments and Research
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- RNA regulation and disease
- melanin and skin pigmentation
- Wound Healing and Treatments
- Body Contouring and Surgery
- Cutaneous lymphoproliferative disorders research
- Skin Protection and Aging
- Nail Diseases and Treatments
- Autoimmune and Inflammatory Disorders
- Facial Rejuvenation and Surgery Techniques
- Cutaneous Melanoma Detection and Management
- Dermatological and COVID-19 studies
- Urticaria and Related Conditions
- Acne and Rosacea Treatments and Effects
- Systemic Sclerosis and Related Diseases
- Psoriasis: Treatment and Pathogenesis
- Cytokine Signaling Pathways and Interactions
- Mast cells and histamine
- Contact Dermatitis and Allergies
- Genital Health and Disease
- Dupuytren's Contracture and Treatments
- Nonmelanoma Skin Cancer Studies
University of California, Irvine
2016-2025
UC Irvine Health
2023-2024
Beckman Laser Institute and Medical Clinic
2018-2024
Lahey Hospital and Medical Center
2024
University Dermatology
2024
Yale University
2021-2023
American Academy of Dermatology
2016-2022
Pfizer (United States)
2022
University of California System
2022
National Alopecia Areata Foundation
2017-2021
Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, oral, selective, reversible inhibitor of Janus kinases 1 2, may interrupt cytokine signaling implicated pathogenesis alopecia areata.We conducted two randomized, placebo-controlled, phase 3 trials (BRAVE-AA1 BRAVE-AA2) involving adults with severe a Severity Tool (SALT) score 50 or higher (range, 0 [no scalp loss] to 100 [complete...
Abstract A preliminary observation of high frequency male pattern hair loss among admitted COVID‐19 patients and suggest that androgen expression might be a clue to severity.
The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged 12 years with alopecia areata (AA). objective this study was to evaluate the safety ritlecitinib integrated analysis four AA. Two cohorts were analyzed: a placebo-controlled all-exposure cohort. Proportions size–adjusted incidence rates (IRs) adverse events (AEs) interest laboratory abnormalities are reported. In cohort (n = 881;...
BackgroundThere are no treatments approved by the Food and Drug Administration for alopecia areata.ObjectiveTo evaluate efficacy safety of baricitinib in patients with ≥50% scalp hair loss a phase 2 study adults areata (BRAVE-AA1).MethodsPatients were randomized 1:1:1:1 to receive placebo or 1 mg, 4 mg once daily. Two consecutive interim analyses performed after all completed weeks 12 36 had discontinued treatment prior these time points. The primary endpoint was proportion achieving...
Content‐valid and clinically meaningful instruments are required to evaluate outcomes of therapeutic interventions in alopecia areata (AA). To develop an Investigator's Global Assessment (IGA) interpret treatment response AA studies. Qualitative interviews were conducted the USA with expert dermatologists patients who had experienced ≥ 50% scalp‐hair loss. Thematic data analysis identified critical evaluated content validity new IGA. Expert clinicians (n = 10) judged success by amount growth...
Abstract Background Alopecia areata (AA) is characterized by hair loss that can affect the scalp and body. This study describes psychosocial burden of AA. Methods Participants diagnosed with AA who had experienced ≥50% according to Severity Tool (SALT) were identified clinicians. A semi-structured interview guide, developed expert clinician input, included open-ended questions explore patients’ experiences living Data thematically analyzed identify concepts relationships. Results ( n = 45,...
BackgroundJanus kinase (JAK) activation is suggested to have a pathological role in alopecia areata (AA). CTP-543, deuterated compound that selectively inhibits JAK1 and JAK2, being developed as an oral treatment for AA.ObjectiveTo assess the safety efficacy of 24-week regimen CTP-543 patients with chronic, moderate-to-severe AA.MethodsIn this phase 2, randomized, double-blind, placebo-controlled, sequential-design trial, were randomized receive (4 mg, 8 or 12 mg) placebo every hours 24...
BackgroundAlopecia areata (AA) is a hair loss disorder that can seriously impact quality of life. Janus kinase (JAK) inhibitors, including deuruxolitinib, have previously demonstrated significant regrowth in AA.ObjectiveThe Phase 3 THRIVE-AA1 randomized, double-blinded, placebo-controlled trial (NCT04518995) evaluated the safety and efficacy oral JAK1/JAK2 inhibitor deuruxolitinib adult patients with AA.MethodsPatients aged 18-65 years ≥50% were randomized to 8 mg twice daily, 12 or placebo...
To determine the effect of patch testing on surgical decision making and outcomes in patients evaluated for suspected metal hypersensitivity related to implants bones or joints.Medical chart review.Tertiary care academic medical center.All who had allergic contact dermatitis orthopedic implants.Patch testing.The surgeon's preoperative choice implant alloy compared with results presence complications postsurgical follow-up.Patients potential from implanted devices (N = 72) were divided into 2...
The current classification for alopecia areata (AA) does not provide a consistent assessment of disease severity.To develop an AA severity scale based on expert experience.A modified Delphi process was utilized. An advisory group 22 clinical experts from the United States formed to this scale. Representatives pharmaceutical industry provided feedback during its development.Survey responses were used draft criteria, aspiring simple that may be easily applied in practice. A consensus vote held...
Current measures of alopecia areata (AA) severity, such as the Severity Alopecia Tool score, do not adequately capture overall disease impact.